Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression
Research output: Contribution to journal › Journal article › Research › peer-review
Current pharmacological treatments for depression have a significant treatment-onset-response delay, an insufficient efficacy for many patients and fail to reverse cognitive dysfunction. Erythropoietin (EPO) has neuroprotective and neurotrophic actions and improves cognitive function in animal models of acute and chronic neurodegenerative conditions and in patients with cognitive decline.
|Number of pages||12|
|Publication status||Published - 2012|